Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

NCT03675139 is registered in ClinicalTrials.gov with Xiaojun Chen as lead sponsor.

NCT NCT03675139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03675139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medroxyprogesterone Acetate (MPA) Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
Lead sponsor
Xiaojun Chen
Phase
Phase 3
Overall status
Completed
Start date
February 26, 2019
Completion date
May 15, 2022
Enrollment
471 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial hyperplasia without atypia